On Oct. 24, 2024, GSK announced an $800 million investment that will bring state-of-the-art drug substance manufacturing and additional drug product manufacturing capabilities to the company’s site in Marietta, Pennsylvania, along with over 200 new jobs. 

The new multi-purpose facility will be capable of manufacturing sterile liquid vaccines and medicines for which there is ever-increasing demand. This facility will also house a state-of-the-art R&D pilot plant to manufacture medicines for clinical trials. Additionally, GSK will establish a new vaccines drug substance facility at the site, dedicated to manufacturing products based on the company’s novel MAPS technology, subsequent to future regulatory submissions and approvals. This expansion will double the size and capacity of the Marietta site. 

Construction of the new facilities is expected to start by the end of this year. The drug substance facility is anticipated to be operational by the end of 2027, with the drug product facility following by the end of 2028.